secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001645113-24-000016
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders elect 10 directors, approve 2024 Omnibus Incentive Plan at AGM
---------------------------------------------------------------------------

- Approximately 85.9M shares (79.8% of eligible) voted at June 5 AGM; all 10 director nominees elected.
- Auditor ratification passed: 80.1M for, 5.7M against, 0.09M abstain.
- Non-binding advisory vote on executive compensation approved: 69.6M for, 1.2M against.
- 2024 Omnibus Incentive Plan approved: 60.1M for (73.7% of votes cast), 10.8M against.
- Say-on-pay frequency set at one year: 70.5M for one year vs 0.4M for three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000016/0001645113-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000016/nvcr-20240605.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer